DEPARTMENT OF HEALTH

NO. 8198 **20 November 2026**

MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT No. 101 OF 1965)

SCHEDULES

The Minister of Health has, in terms of sections 22A(2) and 37A of the Medicines and Related Substances Act, 1965 (Act No. 101 of 1965), on the recommendation of the South African Health Products Regulatory Authority (SAHPRA), made and updated the Schedules.

DR PAKISHE AARON MOTSOALEDI, MP
MINISTER OF HEALTH
DATE: 23/10/2026

This Schedule amends the Schedules as inserted by by Government Notice R.509 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 24727, 10 April 2003; substituted by Government Notice R.935 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 31387, 5 September 2008; and amended by Government Notice R.1230 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 32838, 31 December 2009; Government Notice R.227 (Medicines and Related Substances Act: Schedules)in Government *Gazette* 35149, 15 March 2012; Government Notice R.674 (Medicines and Related Substances Act, 1965: Schedules) in Government Gazette 36827, 13 September 2013, Government Notice R.690 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 36850, 20 September 2013,Government Notice R.104 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 37318, 11 February 2014; Government Notice R.352 (Medicines and Related Substances Act, 1965: Schedules) in, Government *Gazette* 37622, 8 May 2014; Government Notice R.234 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 38586, 20 March 2015; Government Notice R.254 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 39815, 15 March 2016; Government Notice R.254 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 40041, 03 June 2016; Government Notice No.748 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 41009, 28 July 2017; Government Notice No.1261 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 41256, 17 November 2017; Government Notice No.1262 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 42052, 23 November 2018 and Government Notice No.755 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 42477, 23 May 2019; Government Notice No. R219 (Medicines and Related Substances Act, 1965: Schedules) in Government Gazette 430151, 28 February 2020, Government Notice No. R586 (Medicines and Related Substances Act, 1965: Schedules) in Government Gazette 43347, 22 May 2020,Government Notice No. R1375 (Medicines and Related Substances Act1 1965: Schedules) in Government Gazette 44019, 18 December 2020, Government Notice No. 883 (Medicines and Related Substances Act1 1965: Schedules) in Government Gazette 45176, 17 September 2021 and Government Notice No. 2685 (Medicines and Related Substances Act1 1965: Schedules) in Government Gazette 47373, 28 October 2022, Government Notice No. R3261 (Medicines and Related Substances Act1 1965: Schedules) in Government Gazette 48358, 24 March 2023, Government Notice No.5181 (Medicines and Related Substances Act1 1965: Schedules) in Government Gazette 51171, 06 September 2024, and Government Notice No.6466 (Medicines and Related Substances Act1 1965: Schedules) in Government Gazette 53099, 01 August 2025, using the following convention:

- Words in bold and in square brackets (e.g. **[Gamma benzene hexachloride]** in Schedule 1), indicate omission from a Schedule.
- Words underlined with a solid line (e.g. Gamma benzene hexachloride), indicate insertions in a Schedule.

SCHEDULE

In these Schedules, "the Act" means the Medicines and Related Substances Act, 1965 (Act No.101 of 1965)

NOTE: Where an alternative schedule(s) is included in natural parentheses at any point of an inscription, this is provided to indicate one or more alternative scheduling designation/s. This is for information only and shall not be used in the interpretation of such inscription.

SCHEDULE 0

a. All substances referred to in this Schedule are excluded when specifically packed, labelled, sold and used for –

   (i) industrial purposes including the manufacture or compounding of consumer items or products which have no pharmacological action or medicinal purpose, and which are intended to be ingested by man or animals as a food or applied to the body as a cosmetic, and which are approved for such use in terms of the Foodstuffs, Cosmetics and Disinfectants Act, 1972 (Act 54 of 1972) or that are registered in terms of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947); and

   (ii) analytical laboratory purposes.

b. This Schedule shall include all substances or mixtures of such substances containing or purporting to contain substances referred to, including the salts and esters of such substances, where the existence of such salts and esters is possible, **except** where such substances or mixtures of substances are expressly excluded.

This Schedule includes all substances or mixtures of substances subject to registration in terms of the Act, and which are not listed in any of the other Schedules.

SCHEDULE 1

a. All substances referred to in this Schedule are excluded when specifically packed, labelled, sold and used for –

   (i) industrial purposes including the manufacture or compounding of consumer items or products which have no pharmacological action or medicinal purpose; and

   (ii) analytical laboratory purposes.

b. All preparations of substances or mixtures of such substances containing or purporting to contain any substance referred to in this Schedule and includes the following:

(i) The salts and esters of such substances, where the existence of such salts and esters is possible; and

(ii) all preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded.

c. In terms of section 22A(4)(a)(v) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974 (Act 56 of 1974) other than a medical practitioner or dentist may prescribe and supply, only within his/her scope of practice and subject to the indication for use of such substances and medicines and to the conditions determined by the Authority, to patients under his/her care, the Schedule 1 substances and medicines provided for in the Annexures to this Schedule published in the *Gazette* in terms of the Act.

(i) Annexure 1A: **[Emergency Care Provider (Paramedic)]** Paramedic registered with the Health Professions Council of South Africa;
Annexure 1B: **[Emergency Care Provider (Emergency Care Practitioner)]** Emergency Care Practitioner registered with the Health Professions Council of South Africa;
Annexure 1C: Basic Ambulance Assistant;
Annexure 1D: Ambulance Emergency Assistant;
Annexure 1E: Emergency Care Technician;
Annexure 1F: Emergency Care Assistant;

(ii) Annexure 2: Dental Therapist;

(iii) Annexure 3: Optometrist;

(iv) Annexure 4: Podiatrist;

(v) Annexure 5: Oral Hygienist**[s]**.

Amylase (Pancreatin)
Biclotymol
Lipase (Pancreatin)
[Pancreatin]
Protease (Pancreatin)
Nicotine,

a. when intended for human medicinal use as an aid to smoking cessation, when registered and presented as nicotine transdermal patches for continuous application to the skin in strengths up to an including 21mg/ 24 hours or 25 mg/ 16 hours;

b. **[except when registered for human medicinal use as an aid to smoking cessation and presented as nicotine gum or lozenges containing not more**

than 4 mg nicotine per piece; (S0)] when registered as metered sprays containing not more than 1 mg per dose or less;

c. **[except when registered for human medicinal use as an aid to smoking cessation and presented as nicotine gum or lozenges containing more than 4 mg nicotine per piece; (S2)]** **except** when registered for human medicinal use as an aid to smoking cessation and presented as nicotine gum or lozenges containing not more than 4 mg nicotine per piece; (S0)

d. **[except when intended for human medicinal use as an aid to smoking cessation, when registered and presented as nicotine transdermal patches for continuous application to the skin in strengths containing more than 21mg/ 24 hours or 25 mg/ 16 hours; (S2)]** **except** when registered for human medicinal use as an aid to smoking cessation and presented as nicotine gum or lozenges containing more than 4 mg nicotine per piece; (S2)

e. **[when registered as metered sprays containing not more than 1 mg per dose or less]**; **except** when intended for human medicinal use as an aid to smoking cessation, when registered and presented as nicotine transdermal patches for continuous application to the skin in strengths containing more than 21mg/ 24 hours or 25 mg/ 16 hours; (S2)

f. **except** when registered as oral solid dosage forms containing not more than 2 mg; (S2)

g. **except** when registered as inhalers containing not more than 10 mg per cartridge; (S2)

h. **[except when intended for human medicinal use as an aid to smoking cessation or as a substitute for a tobacco product (as defined in the Tobacco Products Control Act, 1993, as amended). (S3)]**

ANNEXURE 1A: [EMERGENCY CARE PROVIDER (PARAMEDIC)] PARAMEDIC REGISTERED WITH HEALTH PROFESSIONS COUNCIL OF SOUTH AFRICA

PARAMEDIC (National Diploma in Emergency Medical Care graduates ***only***) registered with Health Professions Council of South Africa

PARAMEDIC (National Diploma in Emergency Medical Care graduates ***only***)		
LOCAL ANAESTHETIC		
Substance	:	Lignocaine hydrochloride
Indication	:	Local Anaesthetic
Route of Administration	:	Topical application
WATER		
Substance	:	Water for injection
Indication	:	Diluent
Route of Administration	:	Parenteral
WATER		
Substance	:	Water for irrigation
Indication	:	Wound and dressing irrigation
Route of Administration	:	Solution

ANNEXURE 3: OPTOMETRIST

OPTOMETRIST (Bachelor's degree in Optometry – B OPTOM) registered with the Health Professions Council of South Africa.

OPTOMETRIST		
OPHTHALMIC PREPARATIONS: OTHER		
Substance	:	Fluorescein
Indication	:	For diagnostic purpose only i.e. In detecting corneal abrasions and foreign bodies in the eye, in applanation tonometry, in assessing the patency of the nasolacrimal duct and in contact lens fitting procedures
Route of Administration	:	Intra-ocular

OPTOMETRIST (Bachelor's degree in Optometry – B OPTOM) with additional qualifications registered with the Health Professions Council of South Africa in terms of the Health Professions Act, 1974 (Act 56 of 1974) and recognised by the Health Professions Council of South Africa as an authorised prescriber.

OPTOMETRIST (Bachelor's degree in Optometry – B OPTOM with additional qualifications)		
ANALGESIC		
Substance	:	Paracetamol
Indication	:	Mild Pain
Route of Administration	:	Oral
ANALGESIC/ ANTI INFLAMMATORY		
Substance	:	Ibuprofen
Indication	:	Mild to Moderate Pain
Route of Administration	:	Oral
ANTIHISTAMINE/ VASOCONSTRICTOR/ MAST CELL STABILISER		
Substance	:	Loratadine
Indication	:	Atopic dermatitis involving the eyelids
Route of Administration	:	Oral
ANTIHISTAMINE/ VASOCONSTRICTOR/ MAST CELL STABILISER		
Substance	:	Cetirizine; Levocetirizine
Indication	:	Atopic dermatitis involving the eyelids
Route of Administration	:	Oral
SYMPATHOMIMETIC		
Substance	:	Phenylephrine
Indication	:	Minor ocular irritation
Route of Administration	:	Topical (Drops)

ANNEXURE 4: PODIATRIST

PODIATRIST registered with the Health Professions Council of South Africa in terms of the Health Professions Act, 1974 (Act 56 of 1974), holding a BTech Podiatry or BHS Podiatry degree or Podiatrist with a National Higher Diploma and an accredited post graduate certificate.

PODIATRIST		
LOCAL ANAESTHETIC		
Substance	:	Amethocaine/ Tetracaine
Indication	:	Local Anaesthesia
Route of Administration	:	Topical (Cream)
LOCAL ANAESTHETIC		
Substance	:	Chloroethane (Ethyl Chloride)
Indication	:	Local Anaesthesia

PODIATRIST
Route of Administration : Topical (Spray)
LOCAL ANAESTHETIC Substance: Lignocaine/ Lidocaine Indication : Local Anaesthesia Route of Administration : Topical (Pump, Spray, Cream, Patch)
ANALEGESIC, ANTIPYRETIC, ANTI INFLAMMATORY Substance : Paracetamol Indication : Pain Management Route of Administration : Oral
ANALEGESIC, ANTIPYRETIC, ANTI INFLAMMATORY Substance : Naproxen Indication : Pain Management Route of Administration : Oral
ANTI-FUNGAL Substance : Bifonazole Indication : Treatment of fungal infections Route of Administration : Topical
ANTI-FUNGAL Substance : Clotrimazole Indication : Treatment of fungal infections Route of Administration : Topical
ANTI-FUNGAL Substance : Miconazole Indication : Treatment of fungal infections Route of Administration : Topical
ANTI-FUNGAL Substance : Nystatin Indication : Treatment of fungal infections Route of Administration : Topical
ANTI-FUNGAL Substance : Amorolfine Indication : Treatment of fungal infections Route of Administration : Topical
ANTI-FUNGAL Substance : Terbinafine Indication : Treatment of fungal infections Route of Administration : Topical

- END SCHEDULE 1 -

SCHEDULE 2

(i) All substances referred to in this Schedule are excluded when specifically packed, labelled, sold and used for –

(i) industrial purposes including the manufacture or compounding of consumer items or products which have no pharmacological action or medicinal purpose; and

(ii) analytical laboratory purposes.

(ii) All preparations of substances or mixtures of such substances containing or purporting to contain any substance referred to in this Schedule and includes the following:

(i) The salts and esters of such substances, where the existence of such salts and esters is possible; and

(ii) all preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded.

(iii) In terms of section 22A(5)(f) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974 (Act 56 of 1974) other than a medical practitioner or dentist may prescribe and supply, only within their scope of practice and subject to the indication for use of such substances and medicines and to the conditions determined by the Authority, to patients under his/her care, the Schedule 2 substances and medicines provided for in the Annexures to this Schedule published in the *Gazette* in terms of the Act.

(i) Annexure 1A: **[Emergency Care Provider (Paramedic);]** Paramedic registered with the Health Professions Council of South Africa;

Annexure 1B: **[Emergency Care Provider (Emergency Care Practitioner);]** Emergency Care Practitioner registered with the Health Professions Council of South Africa

Annexure 1C: Basic Ambulance Assistant;

Annexure 1D: Ambulance Emergency Assistant;

Annexure 1E: Emergency Care Technician;

Annexure 1F: Emergency Care Assistant;

(ii) Annexure 2: Dental Therapist;

(iii) Annexure 3: Optometrist;

(iv) Annexure 4: Podiatrist.

Aspirin (acetyl salicylic acid), when intended for:

a. the short-term treatment of pain and fever in children or adolescents aged 12 years and older, for a treatment period not exceeding 7 days (S0, S3); and

b. the prophylaxis of cardiovascular disease in adults (S0)

[Carisoprodol]

Levosalbutamol (R-salbutamol; levalbuterol), **except.**

a. when contained in respirator solutions (S3);
b. when intended for injection (S4); and
c. when intended and registered as a stock remedy in terms of the provisions of the Fertilizers, Farm Feed, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 1947).

[Pinaverium]

ANNEXURE 3: OPTOMETRIST

OPTOMETRIST (Bachelor's degree in Optometry – B.OPTOM) registered with the Health Professions Council of South Africa in terms of the Health Professions Act, 1974 (Act 56 of 1974) and recognised by the Health Professions Council of South Africa as an authorised prescriber.

OPTOMETRIST		
ANTIBACTERIAL		
Substance	:	Mupirocin
Indication	:	Impetigo (Eyelids); External Hordeolum, Infected atopic dermatitis
Route of Administration	:	Topical application
ANTIHISTAMINE/ VASOCONSTRICTOR/ MAST CELL STABILISER		
Substance	:	Antazoline
Indication	:	Allergic and Atopic Conjunctivitis
Route of Administration	:	Topical application
ANTIHISTAMINE/ VASOCONSTRICTOR/ MAST CELL STABILISER		

OPTOMETRIST		
Substance	:	Tetrazoline
Indication	:	Minor ocular irritation; Red eye
Route of Administration	:	Topical application
ANTIHISTAMINE/ VASOCONSTRICTOR/ MAST CELL STABILISER		
Substance	:	Oxymetazoline
Indication	:	Minor ocular irritation; Red eye
Route of Administration	:	Topical application
[ANTIHISTAMINE/ VASOCONSTRICTOR/ MAST CELL STABILISER		
Substance	**:**	**Cetirizine; Levocetirizine**
Indication	**:**	**Atopic dermatitis involving the eyelids**
Route of Administration	**:**	**Oral]**
ANTIHISTAMINE/ VASOCONSTRICTOR/ MAST CELL STABILISER		
Substance	:	Sodium Cromoglycate
Indication	:	Vernal Kerato conjunctivitis
Route of Administration	:	Topical application
STEROIDAL ANTI INFLAMMATORY		
Substance	:	Hydrocortisone
Indication	:	Dermatitis, Ectopic or Seborrhoeic Eczema
Route of Administration	:	Topical application

ANNEXURE 4: PODIATRIST

PODIATRIST registered with the Health Professions Council of South Africa in terms of the Health Professions Act, 1974 (Act 56 of 1974), holding a BTech Podiatry or BHS Podiatry degree or Podiatrist with a National Higher Diploma and an accredited post graduate certificate.

PODIATRIST		
Anti-inflammatories		
Substance	:	Diclofenac sodium **[and],** Ibuprofen and Naproxen
Indication	:	Pain management
Route of Administration	:	Oral

PODIATRIST	
ANALEGESIC, ANTIPYRETIC, ANTI INFLAMMATORY	
Substance	: Paracetamol
Indication	: Pain Management
Route of Administration	: Oral
ANTI-BACTERIAL	
Substance	: Fusidic acid
Indication	: Treatment of bacterial infections for foot and lower limbs
Route of Administration	: Topical
ANTI-BACTERIAL	
Substance	: Mupirocin
Indication	: Treatment of bacterial infections of foot and lower limbs
Route of Administration	: Topical
ANTISEPTIC	
Substance	: Povidone-Iodine
Indication	: Treatment of infections for foot and lower limbs
Route of Administration	: Topical

- END SCHEDULE 2 -

SCHEDULE 3

a. All substances referred to in this Schedule are excluded when specifically packed, labelled, sold and used for –

   (i) industrial purposes including the manufacture or compounding of consumer items or products which have no pharmacological action or medicinal purpose; and

   (ii) analytical laboratory purposes.

b. All preparations of substances or mixtures of such substances containing or purporting to contain any substance referred to in this Schedule and includes the following:

   (i) The salts and esters of such substances, where the existence of such salts and esters is possible; and

   (ii) all preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded.

c. In terms of section 22A(5)(f) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974 (Act 56 of 1974) other than a medical

practitioner or dentist may prescribe and supply, only within his/her scope of practice and subject to the indication for use of such substances and medicines and to the conditions determined by the Authority to patients under his/her care, the Schedule 3 substances and medicines provided for in the Annexures to this Schedule published in the *Gazette* in terms of the Act.

(i) Annexure 1A: **[Emergency Care Provider (Paramedic);]** Paramedic Registered with Health Professions Council of South Africa

(ii) Annexure 1B: **[Emergency Care Provider (Emergency Care Practitioner);]** Emergency Care Practitioner Registered with Health Professions Council of South Africa;

(iii) [Annexure 2: Dental Therapist;] Annexure 1C: Basic Ambulance Assistant;

(iv) [Annexure 3: Optometrist;] Annexure 1D: Ambulance Emergency Assistant;

(v) [Annexure 4: Podiatrist.] Annexure 1E: Emergency Care Technician;

(vi) Annexure 1F: Emergency Care Assistant

(vii) Annexure 2: Dental Therapist;

(viii) Annexure 3: Optometrist;

(ix) Annexure 4: Podiatrist.

Aspirin (acetyl salicylic acid), when intended for:

a. use in children less than 12 years of age; and
b. use in children and adolescents aged 12 years and older, for a treatment period exceeding 7 days (S2)

[Cholecalciferol, - see Vitamin D] Colecalciferol, - see Vitamin D.

Febuxostat.

[Glycopyrronium] Glycopyrrolate (Glycopyrronium Bromide).

[Levalbuterol]

Levosalbutamol (R-salbutamol; levalbuterol), when contained in respirator solutions (S2, S4).

[Linagliptin]

Nicotine,

a. when intended for human medicinal use as an aid to smoking cessation or as a substitute for a tobacco product (as defined in the Tobacco Products Control Act, 1993, as amended);

b. **except** when registered for human medicinal use as an aid to smoking cessation and presented as nicotine gum or lozenges containing not more than 4 mg nicotine per piece; (S0)

c. **except** when intended for human medicinal use as an aid to smoking cessation, when registered and presented as nicotine transdermal patches for continuous application to the skin in strengths up to an including 21mg/ 24 hours or 25 mg/ 16 hours; (S1)

d. **except** when intended for human medicinal use as an aid to smoking cessation, when registered and presented as nicotine transdermal patches for continuous application to the skin in strengths containing more than 21mg/ 24 hours or 25 mg/ 16 hours; (S2)

e. **except** when registered for human medicinal use as an aid to smoking cessation and presented as nicotine gum or lozenges containing more than 4 mg nicotine per piece; (S2)

f. **except** when registered as metered sprays containing not more than 1 mg per dose; (S1)

g. **except** when registered as oral solid dosage forms containing not more than 2 mg; (S2)

h. **[except when registered as inhalers containing not more than 10 mg per cartridge. (S2)]**

[V.cholera] Vibrio cholera vaccine.

Vitamin D **[(cholecalciferol)]** colecalciferol, preparations thereof for injection and oral preparations and mixtures thereof containing more than 1 000 I.U. per recommended daily dose, **except** when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947). (S0)

ANNEXURE 1A: [EMERGENCY CARE PROVIDER (PARAMEDIC)] PARAMEDIC REGISTERED WITH HEALTH PROFESSIONS COUNCIL OF SOUTH AFRICA

PARAMEDIC (National Diploma in Emergency Medical Care graduates ***only***) registered with Health Professions Council of South Africa

PARAMEDIC (National Diploma in Emergency Medical Care graduates ***only***)		
PLATELET AGGREGATION INHIBITOR		
Substance	:	Clopidogrel
Indication	:	Platelet aggregation inhibitor
Route of Administration	:	Oral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Dextran
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Hydroxyethyl Starch
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Sodium chloride
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
SELECTIVE β2 AGONISTS		
Substance	:	Salbutamol
Indication:	:	Bronchodilator
Route of Administration	:	Inhalant
SELECTIVE β2 AGONISTS		
Substance	:	Fenoterol
Indication	:	Bronchodilator
Route of Administration	:	Inhalant
MINERAL SUPPLEMENT/ ELECTROLYTE		
Substance	:	Calcium chloride
Indication	:	Positive inotrope- peri-cardiac and cardiac arrest / Electrolyte / Mineral Supplement
Route of Administration	:	Parenteral
OTHER MINERAL SUPPLEMENT		
Substance	:	Magnesium sulphate

PARAMEDIC (National Diploma in Emergency Medical Care graduates ***only***)		
Indication	:	Mineral supplement; prevention and control of seizures and hypertension in toxaemia of pregnancy
Route of Administration	:	Parenteral
CARBOHYDRATES		
Substance	:	Dextrose
Indication	:	Nutrition / Acute Symptomatic HypoglycaemicTreatment
Route of Administration	:	Parenteral
HIGH CEILING LOOP DIURETIC		
Substance	:	Furosemide
Indication	:	Diuretic
Route of Administration	:	Parenteral
ORGANIC NITRATES		
Substance	:	Glyceryl trinitrate
Indication	:	Vasodilator
Route of Administration	:	Oral
ANTI-EMETIC		
Substance	:	Cyclizine
Indication	:	Antihistamine, anti-emetic
Route of Administration	:	Parenteral
CO-ENZYME		
Substance	:	Thiamine (Vitamin B1)
Indication	:	Nutritional supplement/ Vitamin B (Emergency treatment of Wernicke's encephalopathy and Beriberi)
Route of Administration	:	Parenteral
ANALGESIC		
Substance	:	Paracetamol
Indication	:	Analgesic/ Anti-pyrexia
Route of Administration	:	Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Ringers Lactate
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Polygeline
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Sodium Bicarbonate 8,5 %
Indication	:	Metabolic acidosis

PARAMEDIC (National Diploma in Emergency Medical Care graduates ***only***)		
Route of Administration	:	Parenteral
CRYSTALLOID INTRAVENOUS SOLUTIONS (BALANCED SALT SOLUTIONS0		
Substance	:	Sodium, potassium, calcium, magnesium, and chloride
Indication	:	Plasma expanders
Route of Administration	:	Parenteral

ANNEXURE 1B: [EMERGENCY CARE PROVIDER (EMERGENCY CARE PRACTITIONER)] EMERGENCY CARE PRACTITIONER REGISTERED WITH HEALTH PROFESSIONS COUNCIL OF SOUTH AFRICA

EMERGENCY CARE PRACTITIONER (Bachelor of Technology Degree in Emergency Medical Care) registered with Health Professions Council of South Africa

EMERGENCY CARE PRACTITIONER (B Tech: Emergency Medical Care)		
PLATELET AGGREGATION INHIBITOR		
Substance	:	Clopidogrel
Indication	:	Platelet aggregation inhibitor
Route of Administration	:	Oral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Dextran
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Hydroxyethyl Starch
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Sodium chloride
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
SELECTIVE β2 AGONISTS		
Substance	:	Salbutamol
Indication:	:	Bronchodilator
Route of Administration	:	Inhalant

EMERGENCY CARE PRACTITIONER (B Tech: Emergency Medical Care)		
SELECTIVE β2 AGONISTS		
Substance	:	Fenoterol
Indication	:	Bronchodilator
Route of Administration	:	Inhalant
MINERAL SUPPLEMENT/ ELECTROLYTE		
Substance	:	Calcium chloride
Indication	:	Positive inotrope- peri cardiac and cardiac arrest / Electrolyte / Mineral Supplement
Route of Administration	:	Parenteral
OTHER MINERAL SUPPLEMENTS		
Substance	:	Magnesium sulphate
Indication	:	Mineral supplement; prevention and control of seizures and hypertension in toxaemia of pregnancy
Route of Administration	:	Parenteral
CARBOHYDRATES		
Substance	:	Dextrose
Indication	:	Nutrition / Acute Symptomatic Hypoglycaemic Treatment
Route of Administration	:	Parenteral
HIGH CEILING LOOP DIURETIC		
Substance	:	Furosemide
Indication	:	Diuretic
Route of Administration	:	Parenteral
ORGANIC NITRATES		
Substance	:	Glyceryl trinitrate
Indication	:	Vasodilator
Route of Administration	:	Oral
ANTI-EMETIC		
Substance	:	Cyclizine
Indication	:	Antihistamine, anti-emetic
Route of Administration	:	Parenteral
CO-ENZYME		
Substance	:	Thiamine (Vitamin B1)
Indication	:	Nutritional supplement / Vitamin B (Emergency treatment of Wernicke's encephalopathy and Beriberi)
Route of Administration	:	Parenteral
ANALGESIC		
Substance	:	Paracetamol
Indication	:	Analgesic/ Anti-pyrexia

EMERGENCY CARE PRACTITIONER (B Tech: Emergency Medical Care)
Route of Administration : Parenteral
*ANTI-SPASMODIC Substance : Hyoscine butylbromide Indication : Anti-spasmodic Route of Administration : Parenteral
**ARTERIAL SMOOTH MUSCLE AGENT Substance : Hydralazine Indication : Hypertension in pregnancy Route of Administration : Oral
BETA BLOCKER Substance : Labetalol Indication : Hypertension in pregnancy. Route of Administration : Parenteral
**CLASS III ANTI-ARRHYTHMIC Substance : Sotalol Indication : Anti-arrhythmic Route of Administration : Oral/ Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Ringers Lactate Indication : Plasma expanders Route of Administration : Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Polygeline Indication : Plasma expanders Route of Administration : Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS Substance : Sodium Bicarbonate 8,5 % Indication : Metabolic acidosis Route of Administration : Parenteral
**VASODILATOR Substance : Isosorbide dinitrate Indication : Acute pulmonary syndrome/ Acute pulmonary oedema Route of Administration : Parenteral
CALCIUM CHANNEL BLOCKER Substance : Nifedipine Indication : Emergency management of hypertension

EMERGENCY CARE PRACTITIONER (B Tech: Emergency Medical Care)		
Route of Administration	:	Oral
CRYSTALLOID INTRAVENOUS SOLUTIONS (BALANCED SALT SOLUTIONS0		
Substance	:	Sodium, potassium, calcium, magnesium, and chloride
Indication	:	Plasma expanders
Route of Administration	:	Parenteral

ANNEXURE 1C: BASIC AMBULANCE ASSISTANT

BASIC AMBULANCE ASSISTANT registered with Health Professions Council of South Africa		
*SELECTIVE β2 AGONISTS		
Substance	:	Salbutamol
Indication:	:	Bronchodilator
Route of Administration	:	Inhalant
CRYSTALLOID INTRAVENOUS SOLUTIONS (BALANCED SALT SOLUTIONS0		
Substance	:	Sodium, potassium, calcium, magnesium, and chloride
Indication	:	Plasma expanders
Route of Administration	:	Parenteral

ANNEXURE 1D: AMBULANCE EMERGENCY ASSISTANT

AMBULANCE EMERGENCY ASSISTANT registered with Health Professions Council of South Africa		
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Dextran
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Hydroxyethyl Starch
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Sodium chloride
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Ringers Lactate
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Polygeline
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Sodium Bicarbonate 8,5 %
Indication	:	Metabolic acidosis
Route of Administration	:	Parenteral
*CARBOHYDRATES		
Substance	:	Dextrose
Indication	:	Nutrition / Acute Symptomatic Hypoglycaemic Treatment in adults and paediatrics
Route of Administration	:	Parenteral
*CO-ENZYME		
Substance	:	Thiamine (Vitamin B1)
Indication	:	Nutritional supplement/ Vitamin B (Emergency treatment of Wernicke's encephalopathy and Beriberi)
Route of Administration	:	Parenteral

*OTHER MINERAL SUPPLEMENTS		
Substance	:	Magnesium sulphate
Indication	:	Mineral supplement; prevention and control of seizures and hypertension in toxaemia of pregnancy
Route of Administration	:	Parenteral
SELECTIVE β2 AGONISTS		
Substance	:	Salbutamol
Indication:	:	Bronchodilator
Route of Administration	:	Inhalant
CRYSTALLOID INTRAVENOUS SOLUTIONS (BALANCED SALT SOLUTIONS0		
Substance	:	Sodium, potassium, calcium, magnesium, and chloride
Indication	:	Plasma expanders
Route of Administration	:	Parenteral

ANNEXURE 1E: EMERGENCY CARE TECHNICIAN

EMERGENCY CARE TECHNICIAN registered with Health Professions Council of South Africa		
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Dextran
Indication	:	Plasma expanders
Route of Administration	:	Parenteral

PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Sodium chloride
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Ringers Lactate
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Polygeline
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Sodium Bicarbonate 8,5 %
Indication	:	Metabolic acidosis
Route of Administration	:	Parenteral
CARBOHYDRATES		
Substance	:	Dextrose
Indication	:	Nutrition / Acute Symptomatic Hypoglycaemic Treatment in adults and paediatrics
Route of Administration	:	Parenteral
*CO-ENZYME		
Substance	:	Thiamine (Vitamin B1)
Indication	:	Nutritional supplement/ Vitamin B (Emergency treatment of Wernicke's encephalopathy and Beriberi)
Route of Administration	:	Parenteral
OTHER MINERAL SUPPLEMENTS		
Substance	:	Magnesium sulphate
Indication	:	Mineral supplement; prevention and control of seizures and hypertension in toxaemia of pregnancy, Ventricular anti-arrhythmic
Route of Administration	:	Parenteral

ORGANIC NITRATES		
Substance	:	Glyceryl trinitrate
Indication	:	Vasodilator
Route of Administration	:	Oral

SELECTIVE β2 AGONISTS		
Substance	:	Salbutamol
Indication:	:	Bronchodilator
Route of Administration	:	Inhalant
CRYSTALLOID INTRAVENOUS SOLUTIONS (BALANCED SALT SOLUTIONS0		
Substance	:	Sodium, potassium, calcium, magnesium, and chloride
Indication	:	Plasma expanders
Route of Administration	:	Parenteral

ANNEXURE 1F: EMERGENCY CARE ASSISTANT

EMERGENCY CARE ASSISTANT registered with Health Professions Council of South Africa		
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Hydroxyethyl Starch
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Dextran
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Hydroxyethyl Starch
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Sodium chloride
Indication	:	Plasma expanders
Route of Administration	:	Parenteral

PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Ringers Lactate
Indication	:	Plasma expanders
Route of Administration	:	Parenteral

PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Polygeline
Indication	:	Plasma expanders
Route of Administration	:	Parenteral
PLASMA SUBSTITUTES AND COLLOID SOLUTIONS		
Substance	:	Sodium Bicarbonate 8,5 %
Indication	:	Metabolic acidosis
Route of Administration	:	Parenteral
CARBOHYDRATES		
Substance	:	Dextrose
Indication	:	Nutrition / Acute Symptomatic Hypoglycaemic Treatment in adults and paediatrics
Route of Administration	:	Parenteral
*CO-ENZYME		
Substance	:	Thiamine (Vitamin B1)
Indication	:	Nutritional supplement/ Vitamin B (Emergency treatment of Wernicke's encephalopathy and Beriberi)
Route of Administration	:	Parenteral
OTHER MINERAL SUPPLEMENTS		
Substance	:	Magnesium sulphate
Indication	:	Mineral supplement; prevention and control of seizures and hypertension in toxaemia of pregnancy
Route of Administration	:	Parenteral
SELECTIVE β2 AGONISTS		
Substance	:	Salbutamol
Indication:	:	Bronchodilator
Route of Administration	:	Inhalant
CRYSTALLOID INTRAVENOUS SOLUTIONS (BALANCED SALT SOLUTIONS0		
Substance	:	Sodium, potassium, calcium, magnesium, and chloride
Indication	:	Plasma expanders
Route of Administration	:	Parenteral

ANNEXURE 4: PODIATRIST

PODIATRIST registered with the Health Professions Council of South Africa in terms of the Health Professions Act, 1974 (Act 56 of 1974), holding a BTech Podiatry or BHS Podiatry degree or Podiatrist with a National Higher Diploma and an accredited post graduate certificate.

PODIATRIST		
SYMPATHOMIMETIC		
Substance	:	Adrenaline / Epinephrine
Indication	:	Sympathomimetic catecholamine for the management of shock
Route of Administration	:	Parenteral
LOCAL ANAESTHETIC		
Substance	:	Bupivacaine Hydrochloride 2 %
Indication	:	Local Anaesthesia
Route of Administration	:	Parenteral
LOCAL ANAESTHETIC		
Substance	:	Bupivacaine Hydrochloride 2 % with Adrenaline
Indication	:	Local Anaesthesia
Route of Administration	:	Parenteral
[LOCAL ANAESTHETIC		
Substance	**:**	**Levobupivacaine Hydrochloride with Adrenaline**
Indication	**:**	**Local Anaesthesia**
Route of Administration	**:**	**Parenteral]**
[LOCAL ANAESTHETIC		
Substance	**:**	**Lidocaine (Lignocaine) Hydrochloride**
Indication	**:**	**Local Anaesthesia**
Route of Administration	**:**	**Parenteral]**
[LOCAL ANAESTHETIC		
Substance	**:**	**Lidocaine (Lignocaine) Hydrochloride with Adrenaline**
Indication	**:**	**Local Anaesthesia**
Route of Administration	**:**	**Parenteral]**
LOCAL ANAESTHETIC		
Substance	:	Mepivacaine Hydrochloride
Indication	:	Local Anaesthesia
Route of Administration	:	Parenteral

– END SCHEDULE 3 –

SCHEDULE 4

a. All substances referred to in this Schedule are excluded when specifically packed, labelled, sold and used for –

   (i) industrial purposes including the manufacture or compounding of consumer items or products which have no pharmacological action or medicinal purpose; and

   (ii) analytical laboratory purposes.

b. All preparations of substances or mixtures of such substances containing or purporting to contain any substance referred to in this Schedule and includes the following:

   (i) The salts and esters of such substances, where the existence of such salts and esters is possible; and

   (ii) all preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded.

c. In terms of section 22A(5)(f) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974 (Act 56 of 1974) other than a medical practitioner or dentist may prescribe and supply, only within his/her scope of practice and subject to the indication for use of such substances and medicines and to the conditions determined by the Authority, to patients under his/her care, the Schedule 4 substances and medicines provided for in the Annexures to this Schedule published in the *Gazette* in terms of the Act.

   (i) Annexure 1A: **[Emergency Care Provider (Paramedic)]** Paramedic registered with Health Professions Council of South Africa;

   Annexure 1B: **[Emergency Care Provider (Emergency Care Practitioner)]** Emergency Care Practitioner registered with Health Professions Council of South Africa;

   Annexure 1C: Basic Ambulance Assistant;

   Annexure 1D: Ambulance Emergency Assistant;

   Annexure 1E: Emergency Care Technician;

   Annexure 1F: Emergency Care Assistant;

   (ii) Annexure 2: Dental Therapist;

   (iii) Annexure 3: Optometrist;

(iv) Annexure 4: Podiatrist;

(v) Annexure 5: Oral Hygienist.

Abrocitinib.
Adrenaline (epinephrine), when intended for injection. (S2, S3)
Asfotase Alpha.
Atinvicitinib, when intended for veterinary use.
Avalglucosidase alfa.
Avelumab.
Avibactam.
Benserazide.
Binimetinib.

Biological medicines, injectable preparations thereof, when intended for human use and unless listed elsewhere in the Schedules,

a. **except** vaccines, when listed elsewhere in the Schedules and vaccines registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947).

b. but specifically including the following -

(i) Equine anti-human thymocyte globulin;

(ii) Equine gamma globulin;

(iii) Human anti-D immunoglobulin;

(iv) Human anti-thymocyte rabbit immunoglobulin;

(v) Hepatitis A vaccine;

(vi) Hepatitis B immunoglobulin;

(vii) Human normal immunoglobulin, possibly polyvalent or possibly including IgG, IgA, or IgM;

(viii) Human plasma albumin;

(ix) **[*Neiserria meningitides*]** *Neisseria meningitidis* vaccine;

(x) Pneumococcal vaccine, polysaccharide;

(xi) Rabies immunoglobulin;

(xii) Rabies vaccine;

(xiii) Recombinant cholera toxin B subunit;

(xiv) rhDNase-dornase alfa;

(xv) Snake antivenom;

(xvi) Tetanus immunoglobulin;

(xvii) Varicella immunoglobulin;

(xviii) Varicella-zoster virus vaccine;

(xix) Yellow Fever virus, attenuated.

Capivasertib.
Chloroprocaine.
Clascoterone.
Clesrovimab.
Crovalimab.
Danicopan.
Dostarlimab.
Enavogliflozin.
Encorafenib.
Enmetazobactam.
Fezolinetant.
Finerenone.
Foscarbidopa.
Foslevodopa.
[Frusemide.]
Furosemide (Frusemide).
Gadopiclenol.
Ilunocitinib, when intended for veterinary use.
Inavolisib.
Isatuximab.
Lecanemab.
Lenacapavir.
Levosalbutamol (R-salbutamol; levalbuterol), when intended for injection (S2, S3).
Linaclotide.
Linzagolix.
Lonoctocog alfa.
Lorlatinib.
Lurbinectedin.
Marstacimab.
Meningococcal **[Group B]** vaccine.
Netarsudil.
Nirsevimab.
Nonacog beta **[pegol].**
Olaparib.
Pinaverium Bromide

Radiopharmaceuticals, being radioactive compounds and radio-active labelled compounds when used for diagnostic or therapeutic purposes, unless listed elsewhere in the Schedules, and including the following radioisotopes://

(i) Chromium-51;

(ii) ^{14} C – Urea;

(iii) ^{18}F – Fludeoxyglucose (2 - deoxy – 2 - [^{18}F] fluoro- D- glucose

(iv) Gallium-67;

(v) Indium-111;

(vi) Iodine-123;

(vii) Iodine-125;

(viii) Iodine-131;

(ix) **[Phosphorous-32]** Iridium-192;

(x) **[Radium – 223]** Molybdenum-99;

(xi) **[Strontium-89]** Phosphorous-32;

(xii) **[Technetium-99]** Radium – 223;

(xiii) **[Thallium-201]** Strontium-89;

(xiv) **[Xenon-133]** Technetium-99;

(xv) **[Yttrium-90]** Thallium-201;

(xvi) **[Gold – 198]** Xenon-133;

(xvii) Yttrium-90;

(xviii) Gold – 198.

Raxtozinameran.
[Revefanacin] Revefenacin.
Riamilovir.
Rimegepant.
[R-salbutamol, except when intended and registered as a stock remedy in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947).]
Teclistamab.
Tezepelumab.

Tildrakizumab.
Tirzepatide.
Toripalimab.
Varenicline,

a. when intended for nasal administration;
b. except when indicated for oral use as an aid to smoking cessation. (S5)

ANNEXURE 4: PODIATRIST

PODIATRIST registered with the Health Professions Council of South Africa in terms of the Health Professions Act, 1974 (Act 56 of 1974), holding a BTech Podiatry or BHS Podiatry degree or Podiatrist with a National Higher Diploma and an accredited post graduate certificate.

PODIATRIST		
CORTICOSTEROID		
Substance	:	Betamethasone
Indication	:	Anti-inflammatory
Route of Administration	:	Topical
LOCAL ANAESTHETIC		
Substance	:	Levobupivacaine Hydrochloride with Adrenaline
Indication	:	Local Anaesthesia
Route of Administration	:	Parenteral
LOCAL ANAESTHETIC		
Substance	:	Lidocaine (Lignocaine) Hydrochloride
Indication	:	Local Anaesthesia
Route of Administration	:	Parenteral
LOCAL ANAESTHETIC		
Substance	:	Lidocaine (Lignocaine) Hydrochloride with Adrenaline
Indication	:	Local Anaesthesia
Route of Administration	:	Parenteral

ANNEXURE 5: ORAL HYGIENIST[S]

Oral hygienists registered with the Health Professions Council of South Africa (HPCSA) in terms of the Health Professions Act, 1974 (Act 56 of 1974)

– END SCHEDULE 4 –

SCHEDULE 5 AND SPECIFIED SCHEDULE 5

a. All preparations or mixtures of such substances containing or purporting to contain substances that is chemically related and incorporates a structural fragment into its structure that is similar to the structure of a listed substance and /or exhibits pharmacodynamic properties similar to the listed substance referred to in this Schedule include the following:

   (i) The salts and esters of such substances, where the existence of such salts and esters is possible; and

   (ii) all preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded.

   (iii) all homologues of listed substances (being any chemically related substances that incorporate a structural fragment into their structures that is similar to the structure of a listed substance and/or exhibit pharmacodynamic properties similar to the listed substance in the schedules), unless listed separately in the Schedules.

b. In terms of Section 22A(5)(f) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974, other than a medical practitioner or dentist, may prescribe and apply, only within his/her scope of practice and subject to the indication for use of such substances and medicines and to the conditions determined by the Authority, to patients under his/her care, the Schedule 5 and Specified Schedule 5 substances and medicines provided for in the Annexures to this Schedule published in the *Gazette* in terms of the Act.

   (vi) Annexure 1A: **[Emergency Care Provider (Paramedic);]** Paramedic registered with the Health Professions Council of South Africa;

   (vii) Annexure 1B: **[Emergency Care Provider (Emergency Care Practitioner)]** Emergency Care Practitioner registered with Health Professions Council of South Africa;

   (viii) Annexure 1C: Basic Ambulance Assistant

   (ix) Annexure 1D: Ambulance Emergency Assistant

   (x) Annexure 1E: Emergency Care Technician

   (xi) Annexure 1F: Emergency Care Assistant

c. Specified Schedule 5 substances listed in this schedule are subject to additional control in terms of section 22A of the Act as required under the provisions of the 1971 Convention on Psychotropic Substances and are denoted by **

Carisoprodol.
Lasmiditan.
Somatrogon.
Varenicline,

a. **except** when intended for nasal administration (S4).

– END SCHEDULE 5 –

SCHEDULE 6

a. All preparations or mixtures of such substances containing or purporting to contain substances that is chemically related and incorporates a structural fragment into its structure that is similar to the structure of a listed substance and /or exhibits pharmacodynamic properties similar to the listed substance referred to in this Schedule include the following (unless expressly excluded or unless listed in another Schedule):

(i) the isomers of such substances, where the existence of such isomers is possible within the chemical designation;

(ii) the esters and ethers of such substances and of the isomers referred to in (i) as well as the isomers of such esters and ethers, where the existence of isomers of such esters or ethers is possible;

(iii) the salts of such substances and of the isomers referred to in (i), as well as the salts of the esters, ethers and isomers referred to in (ii), where the existence of such salts is possible;

(iv) the isomers of any of the salts referred to in (iii), where the existence of such isomers is possible;

(v) all preparations and mixtures of any of the above.

(vi) all homologues of listed substances (being any chemically related substances that incorporate a structural fragment into their structures that is similar to the structure of a listed substance and/or exhibit

pharmacodynamic properties similar to the listed substance in the schedules), unless listed separately in the Schedules.

b. In terms of Section 22A(5)(f) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974, other than a medical practitioner or dentist, may prescribe and supply, only within his/her scope of practice and subject to the indication for use of such substances and medicines and to the conditions determined by the Authority, to patients under his/her care, the Schedule 6 substances and medicines provided for in the Annexures to this Schedule published in the *Gazette* in terms of the Act.

(i) Annexure 1A: **[Emergency Care Provider (Paramedic);]** Paramedic registered with the Health Professions Council of South Africa;

Annexure 1B: **[Emergency Care Provider (Emergency Care Practitioner)]** Emergency Care Practitioner registered with Health Professions Council of South Africa;

Annexure 1E: Emergency Care Technician.

– END SCHEDULE 6 –

SCHEDULE 7

All preparations or mixture of such substances containing or purporting to contain substances referred to in this Schedule include the following (unless expressly excluded or unless listed in another Schedule):

(i) the isomers of such substances, where the existence of such isomers is possible within the chemical designation;

(ii) the esters and ethers of such substances and of the isomers referred to in (i), as well as the isomers of such esters and ethers, where the existence of isomers of such esters, or ethers is possible;

(iii) the salts of such substances and of the isomers referred to in (i), as well as the salts of the esters, ethers and isomers referred to in (ii), where the existence of such salts is possible;

(iv) the isomers of any of the salts referred to in (iii), where the existence of such isomers is possible;

(v) all preparations and mixtures of any of the above.

(vi) all homologues of listed substances (being any chemically related substances that incorporate a structural fragment into their structures that is similar to the structure of a listed substance and/or exhibit pharmacodynamic properties similar to the listed substance in the schedules), unless listed separately in the Schedules.

Andarine.
Enoborsarm (Ostarine).

[2-Fluorodeschloroketamine] 2-fluorodeschloroketamine.

Hexahydrocannabinol.
Ibutamoren (MK-667, Nutrobal).
Isotonitazene.
Ligandrol (LGD-403).
Metonitazene.
[Pholocodine] Pholcodine.
Protonitazene.
Stenabolic (SR9009).
Testolone (RAD140).
YK-11.

– END SCHEDULE 7–

Commencement

These Schedules as amended come into operation on the date of publication in the Government *Gazette*.